Zoetis Proxy Update: Shareholder Input on Special Meeting Rights

TL;DR

Zoetis is updating shareholders on special meeting rights after 2023 votes, confirming strong support for a 25% threshold.

AI Summary

Zoetis Inc. is providing a supplement to its proxy statement for the May 22, 2024 Annual Meeting of Shareholders. This supplement addresses shareholder feedback and the outcome of two proposals from the 2023 Annual Meeting concerning special meeting rights. Shareholders strongly favored a 25% threshold for requesting special meetings, as indicated by their approval of Proposal 4, a management-backed amendment.

Why It Matters

This filing clarifies Zoetis's response to shareholder votes on special meeting rights, demonstrating the company's engagement with investor feedback and its governance processes.

Risk Assessment

Risk Level: low — The filing is a routine update on corporate governance and shareholder engagement, with no immediate financial risks or significant changes indicated.

Key Numbers

• 25% — Special Meeting Threshold (The percentage of outstanding common stock required for shareholders to request a special meeting, strongly favored by shareholders.)

Key Players & Entities

• Zoetis Inc. (company) — Filer of the DEFA14A
• May 22, 2024 (date) — Date of the 2024 Annual Meeting of Shareholders
• May 6, 2024 (date) — Date of the filing
• 2023 Annual Meeting of Shareholders (event) — Previous meeting where special meeting rights proposals were voted on
• Proposal 4 (proposal) — Management proposal to amend charter for 25% special meeting threshold
• Proposal 5 (proposal) — Non-binding shareholder proposal on special meeting rights

FAQ

From the Filing

0001104659-24-057272.txt : 20240506 0001104659-24-057272.hdr.sgml : 20240506 20240506092340 ACCESSION NUMBER: 0001104659-24-057272 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20240506 DATE AS OF CHANGE: 20240506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zoetis Inc. CENTRAL INDEX KEY: 0001555280 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 460696167 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35797 FILM NUMBER: 24916107 BUSINESS ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-822-7000 MAIL ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 DEFA14A 1 tm2413580d1_defa14a.htm DEFA14A SUPPLEMENT TO PROXY STATEMENT ANNUAL MEETING OF SHAREHOLDERS MAY 22, 2024 May 6, 2024 Dear Fellow Shareholders: In advance of our 2024 Annual Meeting of Shareholders scheduled for May 22, 2024 (the “2024 Annual Meeting”), I am writing to you on behalf of the Board of Directors (the “Board”) of Zoetis Inc. (“Zoetis”) to provide you with some further context on our process and engagement in response to two proposals on special meeting rights that were both approved by shareholders at the 2023 Annual Meeting of Shareholders (the “2023 Annual Meeting”). Shareholders Indicated a Strong Preference for a Special Meeting Right With a 25% Threshold at the 2023 Annual Meeting At the 2023 Annual Meeting of Shareholders, shareholders voted on two proposals regarding the adoption of special meeting rights: (i) Proposal 4, a management proposal that asked shareholders to approve an amendment to Zoetis’ charter to allow shareholders holding 25% of outstanding Zoetis common stock to request special meetings, which the Board recommended on the basis of feedback received from shareholders, and (ii) Proposal 5, a non-binding shareholder proposal submitted by John Chevedden (the “Chevedden Proposal”) requesting the Board take the steps necessary to amend Zoetis’ governing documents to give shareholders owning 10% of outstanding Zoetis common stock the power to call a special shareholder meeting regardless of length of stock ownership. Both proposals passed, with the management proposal receiving significantly higher shareholder support than the Chevedden Proposal. Over 99% of the votes cast (abstentions excluded) supported the management proposal compared to just over 52% of the votes cast (abstentions excluded) that supported the Chevedden Proposal . And even though the Chevedden Proposal narrowly passed at the 2023 Annual Meeting by receiving approximately 52% of the votes cast, Zoetis noted that it received the support of less than 50% of outstanding Zoetis common stock eligible to vote, creating doubt over whether it would pass if proposed as a charter amendment, which would be required to implement such a special meeting right. Zoetis Conducted Extensive Shareholder Outreach and Engagement Prior to the 2023 Annual Meeting and Received Strong Shareholder Feedback Favoring a Special Meeting Right With a 25% Threshold Prior to the 2023 Annual Meeting, members of management and the Board, engaged 16 of our largest shareholders, comprising over 30% of our outstanding shares, on a variety of governance topics, including special meeting rights and the appropriate threshold at which such right should be implemented. Shareholders overwhelmingly indicated their preference for a special meeting right with a 25% threshold rather than a 10% threshold. In supporting the 25% threshold, several of our shareholders expressed the need to balance the right for shareholders to raise issues of importance against the risk that a low threshold of 10% could permit a relatively small group of shareholders to take action without support from the broader shareholder base, thus resulting in an ineffect